Lung Cancer: A Literature Review
Downloads
Lung cancer is a cancer whose onset starts in the lungs where there is an abnormal cell growth that is very fast and uncontrolled. The abnormal cell growth is triggered by deoxyribonucleic acid (DNA) damage, including deletions in the DNA section, inactivation of tumor suppressor genes, activation of proto-oncogenes to oncogenes, the absence of apoptosis, and the activity of the telomerase enzyme. Lung cancer is initiated by oncogeneous activity and inactivation of tumor suppressor genes. Oncogenes are genes that help cells grow and divide and are believed to cause a person to develop lung cancer. In general, lung cancer is divided into two types, namely non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). World Health Organization (WHO) classifies lung cancer based on histopathology into 4 major cell types, namely SCLC, NSCLC which includes adenocarcinoma, squamous cell carcinoma (SCC), and large cell carcinoma (LCC). The difference between the two is that SCLC has a higher aggressiveness than NSCLC. Cancer treatment is based on the type, size, location and stage of the cancer, as well as the patient's overall condition.
Bade BC, Dela Cruz CS. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med 2020; 41: 1–24.
Waddle MR, Ko SJ, May J, et al. Improving Identification of Candidates for Lung Cancer Screening in a High Risk Population. Lung Cancer 2020; 148: 79–85.
Nemesure B, Albano D, Bilfinger T. Lung Cancer Recurrence and Mortality Outcomes Over a 10-Year Period Using a Multidisciplinary Team Approach. Cancer Epidemiol 2020; 68: 101804.
Lariscy JT, Hummer RA, Rogers RG. Lung Cancer Mortality among Never-Smokers in the United States: Estimating Smoking-Attributable Mortality with Nationally Representative Data. Ann Epidemiol 2020; 45: 5–11.
MacRosty CR, Rivera MP. Lung Cancer in Women: A Modern Epidemic. Clin Chest Med 2020; 41: 53–65.
Tolwin Y, Gillis R, Peled N. Gender and Lung Cancer-SEER-Based Analysis. Ann Epidemiol 2020; 46: 14–19.
Ang L, Chan CPY, Yau W-P, et al. Association between Family History of Lung Cancer and Lung Cancer Risk: A Systematic Review and Meta-Analysis. Lung Cancer 2020; 148: 129–137.
Walter J, Tufman A, Holle R, et al. Differences in Therapy and Survival between Lung Cancer Patients Treated in Hospitals with High and Low Patient Case Volume. Health Policy 2020; 124: 1217–1225.
Shao W, Zhou Q, Tang X. Current and Emerging Treatment Options for Lung Cancer in Patients with Pre-Existing Connective Tissue Disease. Pulm Pharmacol Ther 2020; 63: 101937.
Sears CR, Mazzone PJ. Biomarkers in Lung Cancer. Clin Chest Med 2020; 41: 115–127.
Ahmad AS, Mayya AM. A New Tool to Predict Lung Cancer Based on Risk Factors. Heliyon 2020; 6: e03402.
Pasquinelli MM, Tammemägi MC, Kovitz KL, et al. Risk Prediction Model Versus United States Preventive Services Task Force Lung Cancer Screening Eligibility Criteria: Reducing Race Disparities. J Thorac Oncol 2020; 15: 1738–1747.
Lemjabbar-Alaoui H, Hassan OU, Yang Y-W, et al. Lung Cancer: Biology and Treatment Options. Biochim Biophys Acta 2015; 1856: 189–210.
Wang J, Li X, Chen H. Organoid Models in Lung Regeneration and Cancer. Cancer Lett 2020; 475: 129–135.
Hoy H, Lynch T, Beck M. Surgical Treatment of Lung Cancer. Crit Care Nurs Clin North Am 2019; 31: 303–313.
Aragon KN. Palliative Care in Lung Cancer. Clin Chest Med 2020; 41: 281–293.
Adams SJ, Stone E, Baldwin DR, et al. Lung Cancer Screening. Lancet (London, England) 2023; 401: 390–408.
Ramroach S, John M, Joshi A. Lung Cancer Type Classification Using Differentiator Genes. Gene Reports 2020; 19: 100647.
Detterbeck FC, Boffa DJ, Kim AW, et al. The Eighth Edition Lung Cancer Stage Classification. Chest 2017; 151: 193–203.
Mao Y, Yang D, He J, et al. Epidemiology of Lung Cancer. Surg Oncol Clin N Am 2016; 25: 439–445.
Ruiz-Cordero R, Devine WP. Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer. Surg Pathol Clin 2020; 13: 17–33.
Massarelli E, Papadimitrakopoulou V, Welsh J, et al. Immunotherapy in Lung Cancer. Transl Lung Cancer Res 2014; 3: 53–63.
Yuan T, Sun S, Cao Z, et al. Prognostic Immunohistochemical Markers for Small Cell Lung Cancer: A Review. Pathol Res Pract 2021; 217: 153311.
Copyright (c) 2023 Yan Efrata Sembiring, Wiwin Is Effendi, Jeffrey Jeswant Dillon, Heroe Soebroto, Dhihintia Jiwangga Suta Winarno, Purhito Puruhito, I Gusti Agung Made Adnyanya Putra, Abed Nego Okthara Sebayang, Sri Pramesthi Wisnu Bowo Negoro
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (